Diffuse Large B-Cell Lymphoma

Biogen Inc (NASDAQ: BIIB) has exercised its option to participate in the development and commercialization of mosunetuzumab, a CD20xCD3 T-cell engaging bispecific antibody for B-cell non-Hodgkin's lymphoma (NHL), including follicular lymphoma (FL) and diffuse large B-cell...

Roche Holdings AG (OTC: RHHBY) announced results from the Phase 3 POLARIX study of Polivy (polatuzumab vedotin) with MabThera/Rituxan (rituximab) and the chemotherapy regimen R-CHOP. Data were presented at the American Society of Hematology (ASH) Annual Meeting and Exposition. Polivy...

IGM Biosciences Inc (NASDAQ: IGMS) has presented clinical results from its Phase 1 trial of IGM-2323 in patients with advanced B-Cell malignancies. The data were featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. As of September 10, 2021, the data...

Knight Therapeutics Inc has acquired exclusive rights from Incyte Corporation (NASDAQ: INCY) to distribute tafasitamab and pemigatinib (Pemazyre) in Latin America. Related: Incyte's Pemazyre Wins Conditional Approval For Bile Duct Cancer In Canada. Under the agreement...